Protein Sciences Corporation
Sanofi Pasteur Inc. is dedicated to providing innovative influenza vaccines and supporting healthcare professionals with resources, safety data, and effective immunization solutions. They focus on protecting populations, especially older adults, from influenza-related complications through their range of vaccines including Fluzone, Flublok, and Fluzone High-Dose.
Industries
Nr. of Employees
medium (51-250)
Protein Sciences Corporation
Patents
Vectors expressing SARS immunogens, compositions containing such vectors or expression products thereof, methods and assays for making and using
US-8541003-B2
View Details
Vectors expressing SARS immunogens, compositions containing such vectors or expression products thereof, methods and assays for making and using
US-8541003-B2
View DetailsProducts
High-antigen influenza vaccine for adults 65+ (high-dose, 60 mcg HA per strain)
A high‑antigen influenza vaccine formulation intended for active immunization of adults aged 65 years and older; developed and evaluated using randomized trials and real‑world evidence to assess relative vaccine effectiveness against laboratory-confirmed influenza and influenza‑related hospitalizations.
Recombinant hemagglutinin-based influenza vaccine (recombinant HA, 45 mcg HA per strain)
A recombinant HA antigen influenza vaccine produced via a baculovirus-insect cell expression platform, containing a higher antigen dose per strain compared to standard-dose vaccines and evaluated for immunogenicity, efficacy and real-world effectiveness.
Egg-derived influenza vaccine (standard-dose formulations, pediatric and adult use)
Traditional egg-propagated influenza vaccine formulations approved for active immunization across age ranges (including pediatric presentations), with multi-dose and single-dose presentations and specified storage requirements.
High-antigen influenza vaccine for adults 65+ (high-dose, 60 mcg HA per strain)
A high‑antigen influenza vaccine formulation intended for active immunization of adults aged 65 years and older; developed and evaluated using randomized trials and real‑world evidence to assess relative vaccine effectiveness against laboratory-confirmed influenza and influenza‑related hospitalizations.
Recombinant hemagglutinin-based influenza vaccine (recombinant HA, 45 mcg HA per strain)
A recombinant HA antigen influenza vaccine produced via a baculovirus-insect cell expression platform, containing a higher antigen dose per strain compared to standard-dose vaccines and evaluated for immunogenicity, efficacy and real-world effectiveness.
Egg-derived influenza vaccine (standard-dose formulations, pediatric and adult use)
Traditional egg-propagated influenza vaccine formulations approved for active immunization across age ranges (including pediatric presentations), with multi-dose and single-dose presentations and specified storage requirements.
Services
Printable leave-behinds and brochures summarizing pivotal trials, safety data, and real-world evidence for influenza vaccines.
Information on CPT procedure codes, NDC identifiers, and CVX codes for vaccine presentations to support billing and payer reimbursement processes.
Channels and contact resources for ordering vaccine presentations and requesting printed materials or representative support.
Printable leave-behinds and brochures summarizing pivotal trials, safety data, and real-world evidence for influenza vaccines.
Information on CPT procedure codes, NDC identifiers, and CVX codes for vaccine presentations to support billing and payer reimbursement processes.
Channels and contact resources for ordering vaccine presentations and requesting printed materials or representative support.
Expertise Areas
- Influenza vaccine development
- Recombinant vaccine platforms
- Clinical trial design and execution (vaccine efficacy and safety)
- Real-world evidence generation and epidemiologic analysis
Key Technologies
- Baculovirus expression vector system (BEVS) in insect cells
- Egg-based virus propagation
- Cell-culture vaccine production systems
- Hemagglutinin antigen production and purification